Premium
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-15 | Ms. Georgeann F. CoucharaSVP of HR | -281,00 | 45,50k | Sale to Issuer | 161,91 | 8,29k | -3,28% |
| 2026-05-01 | Mr. Alan G. SpoonIndependent Director | -1,36k | 139,59k | Derivative Exercise and Sale | 71,88 - 174,67 | 86,89k | - |
| 2026-05-01 | Mr. Alan G. SpoonIndependent Director | 1,94k | 139,45k | Derivative Exercise and Retained Stock | 71,88 | 86,89k | 2,28% |
| 2026-03-01 | Ms. Georgeann F. CoucharaSVP of HR | -113,00 | 23,80k | Sale to Issuer | 210,64 | 8,57k | -1,30% |
| 2026-03-01 | Ms. Julie Sawyer MontgomeryExec. VP of Diagnostics Platform | -1,08k | 227,49k | Sale to Issuer | 210,64 | 6,18k | -14,88% |
| 2026-03-01 | Mr. Christopher Paul RileyExec. VP of Biotechnology Group & CEO of Cytiva | -1,12k | 234,86k | Sale to Issuer | 210,64 | 20,40k | -5,18% |
| 2026-03-01 | Dr. Jose-Carlos Gutierrez-RamosSenior VP & Chief Science Officer | -284,00 | 59,82k | Sale to Issuer | 210,64 | 8,21k | -3,35% |
| 2026-03-01 | Mr. Matthew E. GuginoExec. VP & CFO | -231,00 | 48,66k | Sale to Issuer | 210,64 | 7,53k | -2,98% |
| 2026-03-01 | Mr. Gregory M. MilosevichExec. VP of Life Sciences Business | -118,00 | 24,86k | Sale to Issuer | 210,64 | 4,11k | -2,79% |
| 2026-03-01 | Mr. Christopher M. BoudaVP & CAO | -170,00 | 35,81k | Sale to Issuer | 210,64 | 6,91k | -2,40% |
| 2026-02-27 | Mr. Mitchell P. RalesCo-Founder & Director | -71,65k | 0,00 | Other Disposition | - | 33,76M | -0,21% |
| 2026-02-24 | Mr. Gregory M. MilosevichExec. VP of Life Sciences Business | -189,00 | 39,54k | Sale to Issuer | 209,19 | 4,91k | -3,71% |
| 2026-02-24 | Ms. Georgeann F. CoucharaSVP of HR | -101,00 | 21,13k | Sale to Issuer | 209,19 | 3,94k | -2,50% |
| 2026-02-24 | Mr. Christopher M. BoudaVP & CAO | -235,00 | 49,16k | Sale to Issuer | 209,19 | 6,52k | -3,48% |
| 2026-02-24 | Dr. Jose-Carlos Gutierrez-RamosSenior VP & Chief Science Officer | -344,00 | 71,96k | Sale to Issuer | 209,19 | 7,63k | -4,31% |
| 2026-02-24 | Mr. Christopher Paul RileyExec. VP of Biotechnology Group & CEO of Cytiva | -242,00 | 50,62k | Sale to Issuer | 209,19 | 15,34k | -1,55% |
| 2026-02-24 | Ms. Julie Sawyer MontgomeryExec. VP of Diagnostics Platform | -372,00 | 77,82k | Sale to Issuer | 209,19 | 5,10k | -6,80% |
| 2026-02-19 | Mr. Gregory M. MilosevichExec. VP of Life Sciences Business | -1,32k | 197,24k | Derivative Exercise and Sale | 58,59 - 208,01 | 5,10k | - |
| 2026-02-02 | Mr. Brian W. EllisInitié | -1,25k | 280,17k | Sale to Issuer | 223,42 | 13,30k | -8,62% |
| 2026-02-02 | Dr. Jose-Carlos Gutierrez-RamosSenior VP & Chief Science Officer | -852,00 | 190,35k | Sale to Issuer | 223,42 | 7,98k | -9,65% |
| 2026-02-02 | Mr. Matthew R. McGrewExec. VP | -1,86k | 414,67k | Sale to Issuer | 223,42 | 28,44k | -6,13% |
| 2026-02-02 | Mr. Christopher Paul RileyExec. VP of Biotechnology Group & CEO of Cytiva | -640,00 | 142,99k | Sale to Issuer | 223,42 | 14,54k | -4,22% |
| 2026-02-02 | Mr. Rainer M. BlairPresident, CEO & Director | -7,75k | 1,73M | Sale to Issuer | 223,42 | 70,20k | -9,94% |
| 2025-11-25 | Mr. Mitchell P. RalesCo-Founder & Director | -40,63k | 9,36M | Vente | 230,27 - 231,19 | 33,83M | -0,12% |
| 2025-11-25 | Mr. Mitchell P. RalesCo-Founder & Director | -22,03k | 0,00 | Other Disposition | - | 33,87M | -0,06% |
| 2025-11-18 | Ms. Teri L. List-StollIndependent Director | -3,30k | 509,94k | Derivative Exercise and Sale | 71,88 - 226,50 | 23,00 | - |
| 2025-11-15 | Mr. Gregory M. MilosevichExec. VP of Life Sciences Business | -35,00 | 7,74k | Sale to Issuer | 221,21 | 4,42k | -0,79% |
| 2025-11-15 | Mr. R. Bradley GraySVP of Strategic Development | -1,40k | 310,14k | Sale to Issuer | 221,21 | 2,94k | -32,31% |
| 2025-11-15 | Ms. Julie Sawyer MontgomeryExec. VP of Diagnostics Platform | -265,00 | 58,62k | Sale to Issuer | 221,21 | 4,62k | -5,43% |
| 2025-11-11 | Mr. Matthew R. McGrewExec. VP | -16,17k | 2,45M | Derivative Exercise and Sale | 62,85 - 214,62 | 30,28k | - |
| 2025-11-12 | Mr. Brian W. EllisInitié | -21,78k | 3,50M | Derivative Exercise and Sale | 58,59 - 219,23 | 14,55k | - |
| 2025-11-12 | Mr. Mitchell P. RalesCo-Founder & Director | -437,00k | 95,57M | Vente | 217,64 - 220,15 | 33,90M | -1,27% |
| 2025-11-10 | Ms. Georgeann F. CoucharaSVP of HR | -4,18k | 510,32k | Derivative Exercise and Sale | 88,24 - 210,44 | 2,63k | - |
| 2025-11-10 | Ms. Georgeann F. CoucharaSVP of HR | -998,00 | 209,89k | Vente | 210,31 | 2,63k | -27,55% |
| 2025-10-31 | Mr. Mitchell P. RalesCo-Founder & Director | -600,00k | 129,64M | Vente | 215,67 - 217,17 | 34,33M | -1,72% |
| 2025-08-22 | Ms. Teri L. List-StollIndependent Director | -2,78k | 586,32k | Vente | 211,06 | 12,00 | -99,57% |
| 2025-07-15 | Dr. Elias Adam ZerhouniIndependent Director | 2,72k | 161,35k | Derivative Exercise and Retained Stock | 59,34 | 15,61k | 21,09% |
| 2025-07-15 | Dr. Elias Adam ZerhouniIndependent Director | -1,21k | 161,43k | Derivative Exercise and Sale | 59,34 - 192,86 | 15,61k | - |
| 2025-07-15 | Mr. John T. SchwietersInitié | 2,72k | 161,35k | Derivative Exercise and Retained Stock | 59,34 | 40,96k | 7,11% |
| 2025-07-15 | Mr. John T. SchwietersInitié | -1,21k | 161,43k | Derivative Exercise and Sale | 59,34 - 192,86 | 40,96k | - |
| 2025-07-15 | Mr. Christopher M. BoudaVP & CAO | -61,00 | 11,76k | Sale to Issuer | 192,86 | 6,27k | -0,96% |
| 2025-07-02 | Ms. Teri L. List-StollIndependent Director | 2,78k | 164,85k | Derivative Exercise and Retained Stock | 59,34 | 2,78k | - |
| 2025-07-02 | Ms. Teri L. List-StollIndependent Director | -1,15k | 164,90k | Derivative Exercise and Sale | 59,34 - 202,73 | 2,78k | - |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
